Cargando…
2764. Generation of a Balanced, Tetravalent Dengue Vaccine Based on Contemporary Strains Using a Computational, Synthetic Biology-Based Platform
BACKGROUND: The WHO estimates that there may be 50 million cases of dengue virus (DENV) infection worldwide every year. There is no safe vaccine against DENV licensed in the United States. The development of a balanced and effective anti-DENV vaccine is vital to preventing morbidity and mortality. C...
Autores principales: | Wang, Ying, Stauft, Charles B, Raviprakash, Kanakatte, Coleman, J Robert, Mueller, Steffen |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6810340/ http://dx.doi.org/10.1093/ofid/ofz360.2441 |
Ejemplares similares
-
Tetravalent dengue DNA vaccine is not immunogenic when delivered by retrograde infusion into salivary glands
por: El Helou, Guy, et al.
Publicado: (2020) -
2764. Experience with dalbavancin in a pediatric hospital
por: Leon, Maria Deza, et al.
Publicado: (2023) -
Fully synthetic platform to rapidly generate tetravalent bispecific nanobody–based immunoglobulins
por: Misson Mindrebo, Laetitia, et al.
Publicado: (2023) -
Safety and Immunogenicity of a Tetravalent Dengue DNA Vaccine Administered with a Cationic Lipid-Based Adjuvant in a Phase 1 Clinical Trial
por: Danko, Janine R., et al.
Publicado: (2018) -
A tetravalent live attenuated dengue virus vaccine stimulates balanced immunity to multiple serotypes in humans
por: Nivarthi, Usha K., et al.
Publicado: (2021)